Abe M, Wakasa H
Department of Pathology I, Fukushima Medical College, Japan.
Fukushima J Med Sci. 1994 Dec;40(2):85-101.
We have investigated the cellular origin and/or pathogenesis of follicular small cleaved cell lymphoma (FSCCL), diffuse small cleaved cell lymphoma (DSCCL) and intermediate lymphocytic lymphoma/lymphocytic lymphoma of intermediate differentiation (ILL/IDL) based on a series of immunologic and molecular genetic (bcl-1, bcl-2 and bcl-3 genes) studies. These studies have led to the conclusion that the cellular origin or pathogenesis of ILL/IDL and DSCCL is distinctly different from that of FSCCL: (1) FSCCL is a neoplastic counterpart of follicular center cells (FCC) of secondary follicles because of the presence of CD10 and bcl-2 gene rearrangement and the absence of CD5 and bcl-1 gene rearrangement; (2) DSCCL and ILL/IDL are a neoplastic counterpart of mantle zone (MZ) B lymphocytes because of the presence of CD5 and bcl-1 gene rearrangement and absence of CD10 and bcl-2 gene rearrangement; and (3) FSCCL scarcely develops into DSCCL, and the previously proposed concept that DSCCL represents a diffuse counterpart of FSCCL does not hold good. These results indicate that DSCCL and ILL/IDL are identical, derived from primary follicular cells or MZB cells of secondary follicles, and should be unified under MZB lymphocyte-derived lymphomas. They are distinguished from FCC-derived lymphomas in morphologic, immunologic, cytogenetic and molecular genetic features. Bcl-1 and bcl-2 genes may be associated with the pathogenesis of FCC-derived lymphoma and MZB lymphocyte-derived lymphoma, respectively.
基于一系列免疫和分子遗传学(bcl-1、bcl-2和bcl-3基因)研究,我们对滤泡性小裂细胞淋巴瘤(FSCCL)、弥漫性小裂细胞淋巴瘤(DSCCL)以及中间淋巴细胞淋巴瘤/中等分化淋巴细胞淋巴瘤(ILL/IDL)的细胞起源和/或发病机制进行了研究。这些研究得出结论,ILL/IDL和DSCCL的细胞起源或发病机制与FSCCL明显不同:(1)FSCCL是次级滤泡的滤泡中心细胞(FCC)的肿瘤对应物,因为存在CD10和bcl-2基因重排,且不存在CD5和bcl-1基因重排;(2)DSCCL和ILL/IDL是套区(MZ)B淋巴细胞的肿瘤对应物,因为存在CD5和bcl-1基因重排,且不存在CD10和bcl-2基因重排;(3)FSCCL很少发展为DSCCL,之前提出的DSCCL是FSCCL的弥漫性对应物这一概念并不成立。这些结果表明,DSCCL和ILL/IDL是相同的,源自初级滤泡细胞或次级滤泡的MZB细胞,应统一归类为MZB淋巴细胞源性淋巴瘤。它们在形态学、免疫学、细胞遗传学和分子遗传学特征上与FCC源性淋巴瘤不同。Bcl-1和bcl-2基因可能分别与FCC源性淋巴瘤和MZB淋巴细胞源性淋巴瘤的发病机制相关。